18[F]F AraG - CellSight Technologies

Drug Profile

18[F]F AraG - CellSight Technologies

Alternative Names: 2'-deoxy-2'-[18F]fluoro-9-β-D-arabinofuranosylguanine; 18[F]F-AraG; 18F-AraG; AraG-18[F]F; F18F-AraG; VisAcT

Latest Information Update: 04 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stanford University
  • Developer CellSight Technologies; University of California at San Francisco
  • Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I Bladder cancer; Cancer; Head and neck cancer

Most Recent Events

  • 19 Dec 2017 Phase-II clinical trials in Non-small cell lung cancer (Diagnosis) in USA (IV) (NCT03311672)
  • 08 Nov 2017 CellSight Technologies signs a collaboration agreement with Boehringer Ingelheim to evaluate 18[F]F AraG in immuno-oncological therapies
  • 17 Oct 2017 University of California, San Francisco and CellSight Technologies plan a phase II trial for Non-small cell lung cancer (Diagnosis) in USA (IV) (NCT03311672)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top